Business Wire

Management reaffirms expectation that first-quarter sales will mark the low point of the year, as improving market conditions support higher sales throughout 2024

Management expects core sales to grow sequentially to approximately $3.4 billion in the second quarter of 2024, with core EPS in the range of $0.42 to $0.46

Corning is well positioned to add more than $3 billion in annualized sales – and deliver strong incremental profit and cash flow – as markets... (continue reading...)

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer, consisting of a non-qualified stock option to... (continue reading...)

SAN FRANCISCO--(BUSINESS WIRE)-- Envoy, the only integrated workplace platform that connects people, spaces, and data, today published the eBook, “Tomorrow’s tech, yesterday’s tactics: Bridging the gap to a future-ready workplace” based on survey data, collected in partnership with Hanover Research, exploring the current workplace landscape. Surveying over 400 executives across key departments like facilities, security, IT, and HR, the report reveals a... (continue reading...)

First-of-its-kind insights to uncover consumer shopping habits available publicly

PORTLAND, Ore.--(BUSINESS WIRE)-- Facteus, the largest provider of consumer transaction data insights in the alternative data industry, today announced the launch of Consumer Insights. This powerful tool, a part of Facteus’ Win the Week™ product suite, provides unparalleled insights into consumer behavior by leveraging real purchase transaction data from a wide range of... (continue reading...)

MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (... (continue reading...)